Back

Impact of dapagliflozin on cardiometabolic outcomes after myocardial infarction according to baseline left ventricular ejection fraction: a DAPA-MI substudy

30 August 2024 (08:00 - 17:30)
Organised by: Logo
Congress Presentation Part of: Risk stratification for midterm outcome after acute coronary syndromes Pharmacotherapy ESC Professional Premium Access ESC Congress 2024 European Society of Cardiology

About the speaker

Photo
Professor David Erlinge

Skane University Hospital, Lund (Sweden)

5 More presentations in this session

Presentation thumbnail
Effects of restrictive vs liberal transfusion strategies on mortality in patients with acute myocardial infarction and anemia: The 6-month follow up primary results of the MINT trial
Professor T. Simon (Paris, FR)
Abstract Slides Video
Presentation thumbnail
Safety of beta-blocker discontinuation in patients after acute coronary syndromes and preserved left ventricular ejection fraction: long-term clinical outcomes from the SPUM-ACS cohort
Doctor N. Johner (Bordeaux, FR)
Abstract Slides Video
Presentation thumbnail
Albumin creatinine index added to the grace score increases its discriminative capacity for mortality at 12 years of follow-up in patients with acute coronary syndrome
Doctor C. Higa (Buenos Aires, AR)
Abstract Slides Video
Presentation thumbnail
Microcirculatory resistance after primary percutaneous coronary intervention predicts residual myocardial damage: a post hoc analysis from the CLEVER-ACS trial
Doctor A. Candreva (Zurich, CH)
Abstract Slides Video
Presentation thumbnail
Impact of baseline thrombocytopenia on outcomes in hospitalizations for acute coronary syndrome and non-elective percutaneous coronary intervention: meta-analysis
Doctor S. Senapati (El Paso, US)
Abstract Slides

Access the full session

Session thumbnail
Risk stratification for midterm outcome after acute coronary syndromes
Video

The Event

Event poster

ESC Congress 2024

30 August - 2 September 2024
You may be interested in
thumbnail
Congress Presentation
Discussant review - DISCOVER SGLT2i
thumbnail
Congress Presentation
Dapagliflozin effect on cardiopulmonary function, reverse cardiac remodelling and biomarkers in a cohort of HFrEF patients
thumbnail
Congress Presentation
The evolving treatment landscape in HFmrEF/HFpEF

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources